Spending determinants Pharmaceutical companies and drug authorities are too discreet in Canada and Quebec when it comes to breaking down consumer spending in retail pharmacies for prescription drugs. The third […]
Introduction For the past two decades in Canada, patient groups funded by pharmaceutical companies have dominated public conversations about the effectiveness and safety of prescription drugs. These groups receive unrestricted […]
Adverse drug reactions (ADRs) are an important part of the process of determining the safety of drugs and treatments. Reports of ADRs by consumers has become a significant portion of the total yet only 1-5% of ADRs are ever reported. The consumer has the biggest stake in ensuring that ADRs are documented and that pharmaceutical manufacturers are held accountable for their mistakes.
One individual broke away from the standard Lipitor “solution” when he experienced continued side-effects from the treatment and began to follow a health alternative including changes in diet and lifestyle. His success is a living example that alternatives not only exist but are obtainable.
The overdiagnosis of diseases like cancer provides no life-saving benefit yet can greatly decrease the patients’ quality of life because of the side effects of the treatments and unjustified fear of a disease that does not threaten their lives.
Off-label prescribing, although legal for physicians in Canada, is illegal for pharmaceutical companies to promote and fines have been ineffective in preventing this practice. Many off-label prescriptions are for conditions difficult to test for, are aimed at women or children and can have serious adverse effects. Drug companies should be required to collect systematic scientific data on these drugs and medical products and seek market authorization for these uses.
Around the globe, medicines regulators approve new drugs after reviewing data from clinical trials. It is these trial data that underlie assuring determinations, like those made by the US Food […]